- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01092702
Varenicline For Smokers In Recovery From Alcohol Dependence
A Pilot Study of Varenicline for Tobacco Dependence Treatment in Recovering Alcoholic Smokers: the Clinical Trial
Study Overview
Detailed Description
This is an open-label, phase II clinical trial. All subjects will be screened for study eligibility after providing informed consent. During the clinic screen visit the subjects are informed of the study, the study informed consent is signed by the subject and staff member, a series of screening tests are conducted and screening criteria are reviewed. Once enrolled in study, the subject will return for a face to face clinic visit weekly for the first 4 weeks (visits 3-6) and then biweekly for the last 8 weeks(visits 7-10). Target quit day is the day after visit 3 (week 1 visit).
During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
Subjects will return weekly for 4 weeks then bi-weekly for the remaining 8 weeks. The study end-date will be Week 12, which is also the end-of-treatment date.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Nicotine Research Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or non-pregnant female cigarette smoker; 18-years-of-age or older and reporting smoking at least an average of 10 cigarettes per day for the past year.
- A history of alcohol dependence based on DSM IV criteria as assessed by the Alcohol Dependence Scale and the physician investigator
- A minimum of 6 months of abstinence from alcohol use as assessed by the physician investigator
- Subject must be able to complete all the study visits
- Subject must be in general good health as determined by medical history, physical exam and physician investigator
- Subject must provide written informed consent to participate in the study.
Exclusion Criteria:
- Current treatment with another investigational drug.
- Current use (within past 30 days) of nicotine replacement therapy, bupropion, rimonabant, varenicline, nortriptyline, clonidine, or other medications known to be effective for treating tobacco dependence.
- Subject has current (past 30 days) major depressive disorder or has a history of another psychiatric disorder such as psychosis or bipolar disorder.
- Current (past 6 months) drug abuse corroborated by the Drug Abuse Screening Test (DAST-20) and physician interview.
- Regular use of other tobacco products (i.e. pipe, cigar, smokeless tobacco) within the past 30 days.
- Females who are pregnant, lactating or likely to become pregnant during the trial and not willing to use an acceptable form of contraception during the medication phase. For women of child-bearing potential, a pregnancy test will be performed prior to entry into the study and at the end of the medication phase.
- A history of a major cardio-vascular event in the past 3 months including unstable angina, acute MI or coronary angioplasty.
- Known allergy to varenicline.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Varenicline
Everyone on study will receive Varenicline daily for 12 weeks
|
During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7.
Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemically Confirmed Abstinence From Smoking
Time Frame: 12 weeks from start of medication
|
The primary endpoint of this trial is biochemically confirmed 7-day point prevalence smoking abstinence at the end of the medication phase (week 12).
Self-reported abstinence from smoking (not even a puff) over the last 7-days will be considered biochemically confirmed by an expired air CO of <8 ppm.
Subjects who discontinue the study or have a missed visit for any reason will be classified as smoking for that visit.
|
12 weeks from start of medication
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James T Hays, MD, Mayo Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08-00672
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Abstinence
-
Ajna HamidovicCompletedTobacco Abstinence SyndromeUnited States
-
Ajna HamidovicCompletedTobacco Abstinence SyndromeUnited States
-
Yale UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Tobacco AbstinenceUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine Withdrawal | Tobacco AbstinenceUnited States
-
Alternatives For GirlsRecruitingAbstinence, SexUnited States
-
IVI BilbaoInstituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
University of Alabama at BirminghamCompletedSmoking Reduction or AbstinenceUnited States
-
University of UtahRecruitingMethamphetamine-dependence | Postpartum AbstinenceUnited States
-
Sir Run Run Shaw HospitalPfizerUnknownSmoking Abstinence | Smoking Cessation InterventionChina
-
NovartisCompleted
Clinical Trials on Varenicline
-
Arizona State UniversityNational Institute on Drug Abuse (NIDA); Pfizer; University of Nevada, Reno; Los...CompletedSmoking Cessation | Withdrawal Symptoms | Tobacco DependenceUnited States
-
PfizerWithdrawn
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Addiction | Crystal Meth Addiction | Amphetamine AddictionUnited States
-
Korea University Anam HospitalCompletedHealthyKorea, Republic of
-
Butler HospitalBrown UniversityCompletedDepressive Disorder | SmokingUnited States
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)Enrolling by invitation
-
PfizerCompletedSmoking CessationUnited States, Korea, Republic of, Taiwan, Canada, Georgia, Russian Federation
-
Oyster Point Pharma, Inc.CompletedHealthy SubjectsUnited States